u/liv_vukovic

do not assume the concentration matches the branded product

New plan year, entirely new criteria, and the denial that had been immovable in the autumn simply did not apply in January.

Agreed — and request the bulletin by number. They have to give it to you.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

salt forms are the recurring argument and the answer is boring

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Yes — the day-two-to-day-four window is so consistent across this board that it is almost diagnostic.

Agreed on writing it down. I could not see the pattern until I had six weeks of it on one page.

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Are you eating in the couple of hours before you sleep?

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

Not convinced by that mechanism. Slowed gastric emptying explains fullness and reflux; it does not explain what you are describing.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

fibre and water before you buy anything to fix it

fatigue plus low intake is usually just low intake

What is the appeal deadline on the letter?

Staff name removed.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

hair shedding follows the weight loss, not the drug, and it stops

the shortage list is the whole legal hinge and people skip it

Has anything else changed in the same window?

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.

do not assume the concentration matches the branded product

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

Reflux was the one that got me. Stopped eating in the three hours before bed and it went from nightly to almost never.

the price difference is mostly the intake, not the vial

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

the label on a compounded vial is a legal document, read it

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

fibrosis improvement without worsening steatohepatitis is the phrase to learn

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Nobody warned me about fatigue and I would have liked the warning. It was not dangerous, it was just deeply unpleasant and completely unexpected.

Severe or persistent abdominal pain sits outside the pattern this board can usefully discuss. The honest answer there is that it needs someone who can examine you.